Azacytidine for the treatment of myelodysplastic syndromes in the elderly

被引：0

作者：

Campelo M.D. ^{[1
]}

Delgado R.G. ^{[2
]}

Molias A.C.G. ^{[3
]}

Sanchez J.F. ^{[4
]}

机构：

[1] Department of Hematology, Hospital Universitario, Salamanca

[2] Department of Hematology, Hospital Virgen de la Victoria, Malaga

[3] Department of Hematology and Hemotherapy, Hospital Universitario Miguel Servet, Zaragoza

[4] Department of Hematology and Hemotherapy, Hospital San Pedro, Logroño

来源：

Advances in Therapy | 2011年 / 28卷 / Suppl 2期

关键词：

5-Azacytidine; Elderly; Myelodysplastic syndromes;

D O I：

10.1007/s12325-010-0097-3

中图分类号：

学科分类号：

摘要：

The management of myelodysplastic syndromes (MDS) in elderly patients is a significant clinical problem. The therapeutic options range from observation alone for patients with lowrisk disease, lenalidomide for patients with 5q-syndrome, to 5-azacytidine (5-AZA) for patients with higher risk of disease. In this paper, we summarize the clinical course of three patients with high-risk MDS treated with 5-AZA as well as the management and supportive care measures for adverse events. As expected, based on available clinical trials data, the agent resulted in clinical and hematological improvement in these patients with acceptable side effects. 5-AZA is an attractive option for elderly patients with high-risk MDS. © Springer Healthcare 2011.

引用

页码：10 / 15

页数：5

共 17 条

[1]

Lee S.J., Lindquist K., Segal M.R., Covinsky K.E., Development and validation of a prognostic index for 4-year mortality in older adults, Journal of the American Medical Association, 295, 7, pp. 801-808, (2006)

[2]

Bennett J.M., Catovsky D., Daniel M.T., Proposals for the classification of the myelodysplastic syndromes, British Journal of Haematology, 51, 2, pp. 189-199, (1982)

[3]

Swerdlow S.H., Campo E., Harris N.L., Et al., WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues, (2008)

[4]

Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., Sanz M., Vallespi T., Hamblin T., Oscier D., Ohyashiki K., Toyama K., Aul C., Mufti G., Bennett J., International scoring system for evaluating prognosis in myelodysplastic syndromes, Blood, 89, 6, pp. 2079-2088, (1997)

[5]

Malcovati L., Germing U., Kuendgen A., Della P.M.G., Pascutto C., Invernizzi R., Giagounidis A., Hildebrandt B., Bernasconi P., Knipp S., Strupp C., Lazzarino M., Aul C., Cazzola M., Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes, Journal of Clinical Oncology, 25, 23, pp. 3503-3510, (2007)

[6]

Park M.J., Kim H.J., Kim S.H., Et al., Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS, Eur J Haematol, 81, pp. 364-373, (2008)

[7]

Hasse D., Cytogenetic features in myelodysplastic syndromes, Ann Hematol, 87, pp. 515-526, (2008)

[8]

List A., Dewald G., Bennett J., Giagounidis A., Raza A., Feldman E., Powell B., Greenberg P., Thomas D., Stone R., Reeder C., Wride K., Patin J., Schmidt M., Zeldis J., Knight R., Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion, New England Journal of Medicine, 355, 14, pp. 1456-1465, (2006)

[9]

Sierra J., Perez W.S., Rozman C., Carreras E., Klein J.P., Douglas R.J., Davies S.M., Lazarus H.M., Bredeson C.N., Marks D.I., Canals C., Boogaerts M.A., Goldman J., Champlin R.E., Keating A., Weisdorf D.J., De Witte T.M., Horowitz M.M., Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia, Blood, 100, 6, pp. 1997-2004, (2002)

[10]

Aul C., Gatterman N., Schneider W., Age related incidence and other epidemiological aspects of myelodysplastic syndromes, Br J Haematol, 82, pp. 358-367, (1992)

← 1 2 →